Free Newsletter
Novartis inks pact to enter Japanese vax market
Novartis has struck a deal with Takeda that will allow the Swiss pharma giant entry into the world's third largest vaccine market.
Takeda has agreed to pay Novartis a little more than a million dollars upfront along with milestones and royalties for Vaxem-Hib, a vaccine for the Haemophilus influenza Type B (Hib). Takeda takes on responsibility for clinical trials in Japan and will file the NDA for the vaccine, which will be sold under the Novartis name.
Japan's vaccine market is valued at $640 million and is widely expected to grow more.
- read the report from Reuters
Related Articles:
Novartis pays $20M up front for vax program
Xoma, Novartis restructure vaccine agreement
Novartis plans trials for growing vaccines pipeline
Novartis eyes vaccines with Protez purchase
Comments
Post new comment
Paid Research Reports
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges
- Pharmaceuticals: United States Industry Guide
- Generic Benchmarking: Brand Erosion at Patent Expiry
- Key Players in Pharmaceutical Contract Manufacturing: Market developments, outsourcing hotspots and growth strategies
More Research Reports >>
Click here to get the FierceVaccines email newsletter for FREE!
Be the first to comment